Oneview Healthcare Chess Depository Interests repr 1 (ONE) AI Stock Analysis

• Market Cap: AU$149.61M
• Dividend Yield: N/A
• Average Volume (3M): 344.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 21.56%
• EPS Growth: -24.08%
• Country: AU
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 767,229,900
• 10 Day Avg. Volume: 303,620
• 30 Day Avg. Volume: 344,030
• PEG Ratio: 0.76
• Price to Book (P/B): 47.09
• Price to Sales (P/S): 14.39
• P/FCF Ratio: -20.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.45
• Price Target Upside: 73.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.01
• Revenue Forecast (FY): AU$15.75M

• Rating: 48 Neutral
• Price Target: AU$0.19 ▼(-25.77% Downside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is held back primarily by weak financial performance (ongoing large losses and cash burn) and bearish technical trend (below key moving averages with negative MACD). This is partially offset by constructive earnings-call commentary pointing to sustained growth, cost reductions, and expanding commercial access (Baxter/GPO), while valuation support is limited due to loss-making results and no dividend.

Positive Factors

Consistent revenue growth & deployment momentum

Sustained top-line growth and accelerating deployments indicate product-market fit and expanding recurring revenue. A larger installed base (endpoints target +20% in 2026) supports future ARR, improves unit economics as fixed costs scale, and creates a more stable revenue foundation over the medium term.

Baxter partnership & GPO market access

GPO inclusion materially broadens U.S. commercial reach and shortens procurement friction with major health systems. Structurally, this expands the addressable market and provides a repeatable channel for enterprise sales, improving long-term go-to-market efficiency if conversion executes.

AI-driven engineering productivity gains

Measurable SDLC productivity gains lower development costs and accelerate feature delivery, enabling faster deployments and potentially higher gross margins over time. Operationalizing AI across engineering is a durable structural lever to improve time-to-market and reduce incremental R&D expense.

Negative Factors

Persistent negative cash flow and operating losses

Ongoing cash burn and repeated operating losses force reliance on external financing, creating dilution and limiting strategic optionality. Without sustained margin expansion or materially higher recurring revenue, the company faces balance sheet pressure that can constrain growth investments over the next several quarters.

Long sales cycles and pipeline conversion timing

Extended procurement timelines delay revenue recognition and make forecasting and cash planning difficult. Reliance on large, slow enterprise deals increases execution risk; if conversion stalls, revenue and margin improvement plans tied to that pipeline may not materialize within the expected 2-6 month horizon.

Growth reliant on upsell and enterprise expansion

A high share of future upside depends on upselling existing customers and large enterprise conversions. This concentration means revenue growth is sensitive to customer budget cycles, churn, and successful rollouts; failure to convert white space would stall scalable, predictable ARR growth.

Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model

Company Description

Oneview Healthcare Chess Depository Interests repr 1 (ONE) is a healthcare technology company that focuses on providing innovative digital solutions to enhance patient and operational outcomes in the healthcare sector. The company primarily offers a digital patient engagement platform that streamlines communication between healthcare providers and patients, facilitates data sharing, and improves overall patient experience. Oneview Healthcare operates within the broader healthcare technology industry, catering to hospitals, clinics, and other healthcare organizations seeking to modernize their patient care processes.

How the Company Makes Money

null

Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview

Summary

Revenue growth is strong (FY25 up ~21%), and leverage appears low where provided, but financial quality remains weak due to large ongoing operating/net losses and persistent negative operating and free cash flow, indicating continued reliance on external funding until profitability improves.

Income Statement

Revenue has grown steadily in recent years (2025 up ~21% vs. 2024; 2024 and 2023 low-single-digit growth), and gross profit remains solid in dollar terms. However, the company continues to post very large operating and net losses each year (2025 net loss ~-$12.5M on ~$11.9M revenue), implying operating costs remain structurally high relative to its current scale. Overall, the top line trend is improving, but profitability and operating leverage remain the clear weakness.

Balance Sheet

Leverage looks manageable in the years where it’s provided (debt-to-equity ~0.09 in 2024 and ~0.10 in 2023), which reduces near-term balance sheet risk versus highly levered peers. That said, equity has been volatile (notably lower in 2025 vs. 2024) and returns on equity are deeply negative due to ongoing losses, signaling continued balance sheet pressure if losses persist.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are negative across all periods shown, including 2025 operating cash flow of about -$8.3M and free cash flow of about -$8.4M. While free cash flow improved versus 2024, the business is still consuming cash rather than funding itself internally, increasing dependence on external financing until profitability and cash burn improve.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	11.93M	9.89M	9.40M	8.92M	9.73M
Gross Profit	7.12M	6.67M	6.16M	5.35M	5.31M
EBITDA	-10.48M	-11.26M	-7.88M	-12.09M	-8.01M
Net Income	-12.51M	-10.84M	-8.93M	-10.87M	-8.19M
Balance Sheet
Total Assets	15.49M	25.96M	21.92M	12.75M	21.09M
Cash, Cash Equivalents and Short-Term Investments	4.60M	13.83M	11.55M	6.41M	15.18M
Total Debt	1.99M	1.15M	935.32K	543.01K	1.20M
Total Liabilities	11.84M	12.71M	12.78M	10.50M	11.19M
Stockholders Equity	3.65M	13.25M	9.14M	2.26M	9.90M
Cash Flow
Free Cash Flow	-8.38M	-10.52M	-7.79M	-10.24M	-4.09M
Operating Cash Flow	-8.32M	-10.47M	-7.26M	-10.20M	-4.03M
Investing Cash Flow	-116.31K	-459.78K	-521.38K	-44.52K	-65.26K
Financing Cash Flow	-294.26K	13.14M	13.04M	-100.11K	12.22M

Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.29, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 33.13 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ONE.

Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	67 Neutral	AU$141.01M	26.51	4.37%	―	10.06%	―
CGS	66 Neutral	AU$370.56M	13.97	26.76%	0.88%	21.47%	89.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONE	48 Neutral	AU$149.61M	-13.72	-226.75%	―	21.56%	-24.08%
M7T	47 Neutral	AU$62.28M	-6.28	-23.86%	―	15.99%	22.05%
PCK	45 Neutral	AU$31.35M	-3.13	-1009.84%	―	25.98%	22.10%
BMT	44 Neutral	AU$42.14M	-5.70	-14.19%	―	3.61%	-17.03%

Oneview Healthcare Chess Depository Interests repr 1 Corporate Events

Oneview Healthcare Corrects Classification of Prior RSU Issuance Under ASX Rules

Oneview Healthcare has issued an updated notice to the ASX correcting how a tranche of previously announced restricted share units was classified under the exchange’s listing rules. Of the 15,355,984 RSUs disclosed on 18 March 2025, the company now clarifies that 3,613,180 were issued under its LR 7.1 placement capacity rather than under an LR 7.2 exemption linked to resolutions in its 2025 AGM notice.

The revision is largely administrative but provides greater transparency over Oneview’s use of its placement capacity and compliance with ASX listing rules. By clarifying the allocation between general placement capacity and exempt issues, the update helps investors more accurately assess the company’s remaining headroom for future equity-based incentives or capital management activity.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.22 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Launches Dual Equity Raising via Placement and SPP

Oneview Healthcare plans to raise new equity capital through the issue of CHESS Depositary Interests on the ASX via both a placement and a securities purchase plan. The structure targets a maximum of 63,157,895 CDIs under the placement and up to 10,526,316 CDIs under the securities purchase plan, with record, closing, and issue dates set across March and April 2026.

The dual-capital-raising approach is designed to bring in institutional and retail investor funds, potentially strengthening the company’s balance sheet and funding future growth initiatives. Existing shareholders are offered participation through the securities purchase plan, while the larger placement may broaden the register and could have implications for ownership dilution, trading liquidity, and the company’s financial flexibility.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Plans Major CDI Placement to Raise Capital

Oneview Healthcare Plc has notified the ASX of a proposed issue of up to 36,842,105 CHESS Depositary Interests on a 1:1 basis as part of a placement or similar capital-raising transaction. The new securities are expected to be issued on 25 May 2026, signalling an upcoming equity raise that could strengthen the company’s funding position and support its ongoing operations and growth plans.

The placement structure suggests Oneview is seeking additional capital from investors via the ASX, which may provide greater financial flexibility for executing its strategy in the healthcare technology market. The proposed issue, once completed and quoted, will expand the company’s listed securities base and may have implications for shareholder dilution and market liquidity.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Raises A$19m in Upsized Placement and Launches SPP to Fund AI and Growth

Oneview Healthcare has secured commitments for a two‑tranche institutional placement raising A$19 million at A$0.19 per new CDI, with the offer upsized and strongly backed by existing shareholders and new international investors. The company’s largest shareholder, Manderrah Pty Ltd as trustee of the GJJ Family Trust, will contribute A$7 million in the second tranche, subject to shareholder approval at an extraordinary general meeting expected in May 2026.

Alongside the placement, Oneview will launch a security purchase plan for eligible investors in Australia, New Zealand and Ireland to raise up to approximately A$2 million at the same A$0.19 issue price, with participation optional and potential scale‑back at the company’s discretion. Proceeds will be used to bolster the balance sheet, fund deployments that convert its signed pipeline into revenue‑generating endpoints, and accelerate development of its AI‑powered virtual patient assistant Ovie and other automation and AI initiatives, reinforcing its positioning as health systems seek technology‑enabled efficiency in a challenging macro and healthcare environment.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Issues 620,000 Restricted Share Units Under Employee Incentive Plan

Oneview Healthcare plc has notified the market of the issue of 620,000 restricted share units under its employee incentive scheme, designated as unquoted equity securities on the ASX. The new instruments, which are subject to transfer restrictions until a specified expiry, reflect the company’s ongoing use of equity-based compensation to retain and motivate staff, potentially aligning employee interests more closely with long-term shareholder value.

The restricted share units, recorded under the ASX security code ONEAF, were issued with an effective date of 17 December 2025, with the formal announcement lodged on 23 February 2026. While the securities will not be quoted on the ASX until restrictions lapse, their issuance modestly increases Oneview’s pool of incentive equity and may have a small dilutive effect over time if converted into fully tradable shares.

The most recent analyst rating on (AU:ONE) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Sets Date for FY25 Results and Investor Call

Oneview Healthcare PLC has scheduled the release of its full-year results for the financial year ended 31 December 2025 on 12 February 2026, and will host a conference call for investors and analysts on the same day at 8:00am AEDT, led by CEO James Fitter and CFO Darragh Lyons. The announcement sets expectations for upcoming financial disclosures and provides stakeholders with a formal forum to engage with management on the company’s performance and strategic direction.

The most recent analyst rating on (AU:ONE) stock is a Sell with a A$0.29 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Narrows Cash Outflows and Gains Strategic Access to Major US Health System

Oneview Healthcare reported a cash balance of €4.6 million at 31 December 2025 and a reduced net operating cash outflow of €1.4 million for the quarter, reflecting higher customer receipts, lower product manufacturing and operating costs, and reduced marketing spend compared with the prior year period. Operationally, the company sustained strong commercial momentum by securing a new five-year contract with Peterson Health in Texas, expanding deployments to nearly 14,900 live endpoints, progressing major implementations at Inova Health and other U.S. hospitals, and achieving a key milestone in its partnership with Baxter, which has now added Oneview’s products to a national care communication purchasing agreement for one of the ten largest U.S. health systems, potentially opening access to more than 85 hospitals and 15,000 beds, although future orders are not guaranteed.

The most recent analyst rating on (AU:ONE) stock is a Sell with a A$0.29 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.